Stocks making the biggest moves midday: Shopify, Advanced Micro Devices, PayPal, Intel, Coinbase & more

Midday trading was driven by a mixed batch of earnings, guidance updates, and deal news, with sharp stock-specific moves ranging from Rockwell Automation's 10% gain on a Q2 beat and raised FY2026 outlook to Shopify's nearly 15% drop on softer revenue-growth guidance. Other notable movers included Huntington Ingalls (-11%) on free cash flow guidance, DuPont (+8%) on higher full-year guidance and a $275 million buyback, and Bullish (+12%) after announcing a $4.2 billion acquisition of Equiniti. AI-related layoffs pressured Coinbase (-3%) and PayPal (-9%), while Intel (+13%) rallied on reports of early talks with Apple over chipmaking services.

Analysis

The market is rewarding earnings beats only when they come with either credible reacceleration or visible capital return; otherwise it is punishing any sign that demand or monetization is normalizing. That creates a clear factor split: quality industrials and healthcare are getting re-rated on guidance durability, while software and payments are being treated as longer-duration exposure to slowing transaction growth and AI-led cost rationalization. The second-order read-through is that management teams are now using buybacks and headcount cuts as a defense mechanism, but the market is more interested in whether those actions preserve margin or merely mask decelerating end demand.

The biggest competitive implication is in digital infrastructure. The Intel headline is less about near-term foundry economics than about validating a multi-supplier search by hyperscale/consumer silicon buyers; if Apple is willing to broaden its manufacturing optionality, that strengthens the bargaining position of the whole advanced packaging and wafer ecosystem, but it also raises the probability that incumbent leaders face pricing pressure before volume recovery. In crypto, the Bullish acquisition is a signal that regulated market plumbing is becoming strategically valuable; that helps the exchange layer and related custody/transfer-adjacent assets more than pure trading volumes, which remain cyclical and fee-compressed.

The healthcare and biotech tape suggests asymmetric upside where clinical derisking can overwhelm broad market caution. Cytokinetics is the type of name that can sustain momentum for months if the sell-side starts modeling commercialization probability, but it also becomes vulnerable if the market shifts from trial success to payer/access scrutiny. By contrast, consumer internet names with user or bookings softness are being marked down immediately because their path to reacceleration is less controllable and more dependent on ad-market or engagement inflection that usually takes quarters, not days.

The contrarian setup is that several of the losers may be closer to inflection than the tape implies: cost cuts at PayPal and Coinbase can create near-term EPS support even if top-line growth stays mediocre, while Shopify’s slowdown may be a digestion phase after a strong run rather than a structural break. The risk is that investors underappreciate how quickly AI and automation can lower the bar for labor-heavy platforms, but overappreciate the near-term ability of those savings to offset slower revenue. For the winners, the reversal risk is mostly guidance fatigue: once the forward numbers stop improving, the multiple expansion can disappear faster than the operating beats did.

Key Decisions for Investors

• Fade the post-earnings gap in SHOP via a short-dated put spread or small tactical short for 2-4 weeks; the setup is still vulnerable if growth normalization continues to dominate margin leverage, with a favorable asymmetry if the market re-rates it as a slower-growth platform.
• Buy CYTK on pullbacks for a 3-6 month hold; use a call spread rather than stock if available. The clinical catalyst can support a multi-month rerating, but size modestly because trial winners often give back 20-30% on commercialization or safety noise.
• Pair long ROK / short FISV or PYPL over the next 1-2 months; the market is favoring industrial execution with clearer capital return and punishing payments names where AI-driven restructuring may not be enough to stabilize growth.
• Trade INTC as a tactical momentum long against MU or AAPL only on weakness, not strength, for 1-3 weeks. The catalyst is sentiment re-rating around foundry optionality, but the risk/reward is poor if the Apple rumor cools and the move retraces quickly.
• Add BUD on dips for a 2-6 month recovery trade; the key is that visible demand resilience plus buyback/capital return can support multiple expansion even if volume growth remains uneven.